



NECTAR LIFESCIENCES LIMITED

Regd. Office: Vill. Saidpura, Tehsil Derabassi, Distt. Mohali, (Punjab)

Unaudited Financial Results for the Quarter ended 31.03.2011 (Rs in Lacs)

S. No	PARTICULARS	Quarter ended	Quarter ended	Year ended	Year ended
		31.03.2011	31.03.2010	31.03.2011	31.03.2010
		Unaudited	Unaudited	Unaudited	Audited
1.	Gross Sales/Income from Operations	35644.47	24662.97	111576.59	88582.17
	Less : Excise Duty	1763.02	496.02	5954.50	4002.26
	Net Sales / Income from Operations	33881.45	24166.95	105622.09	84579.91
	Other Operating Income	254.56	199.59	700.10	409.59
	Total Operating Income	34136.01	24366.54	106322.19	84989.50
2.	Expenditure				
	a. (Increase)/decrease in stock in trade	114.55	95.98	(2377.53)	939.51
	b. Consumption of Raw Material	23644.63	16322.04	72689.16	53491.67
	c. Employees Cost	1069.13	792.34	3937.66	3187.70
	d. Depreciation	1116.50	945.91	4552.00	3874.64
	e. Other Expenditure	2742.85	2188.39	8754.03	7457.01
	Total Expenditure	28687.66	20344.66	87555.32	68950.53
3.	Profit from Operations before Other Income, Interest & Exceptional Items (1-2)	5448.35	4021.88	18766.87	16038.97
4.	Other Income	1336.19	1277.68	1354.43	1485.73
5.	Profit before Interest & Exceptional Items (3+4)	6784.54	5299.56	20121.30	17524.70
6.	Interest (includes the Premium on FCCB redemption for the financial year 2010-11)	3480.69	1972.11	7666.36	6028.44
7.	Profit after Interest but before Exceptional Items (5-6)	3303.85	3327.45	12454.94	11496.26
8.	Exceptional Items	0.00	0.00	0.00	0.00
9.	Profit from ordinary activities before tax (7+8)	3303.85	3327.45	12454.94	11496.26
10.	Tax Expenses	121.15	665.37	2267.52	2298.82
11.	Net Profit from ordinary activities after tax (9-10)	3182.70	2662.08	10187.42	9197.44
12.	Extraordinary Item (net of tax expense)	0.00	0.00	0.00	0.00
13.	Net Profit for the period (11-12)	3182.70	2662.08	10187.42	9197.44
14.	Paid up Equity Share Capital (Face Value per share : Re.1/-)	2242.61	2242.61	2242.61	2242.61
15.	Reserves excluding Revaluation Reserves				59855.37
16.	Earnings per Share (EPS)				
	Basic EPS before Extraordinary items	1.42	1.67	4.54	5.81
	Diluted EPS before Extraordinary items	1.42	1.23	4.54	4.28
	Basic EPS after Extraordinary items	1.42	1.67	4.54	5.81
	Diluted EPS after Extraordinary items	1.42	1.23	4.54	4.28
17.	Public Shareholding				
	- Number of Shares	124969970	126119330	124969970	126119330
	- Percentage of Shareholding	55.73	56.24	55.73	56.24
18.	Promoters and Promoter Group Shareholding				
	a) Pledged/Encumbered				
	- Number of Shares	0	0	0	0
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	0.00	0.00	0.00	0.00
	- Percentage of Shares (as a % of the total share capital of the company)	0.00	0.00	0.00	0.00
	b) Non-encumbered				
	- Number of Shares	99291000	98141640	99291000	98141640
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the company)	44.27	43.76	44.27	43.76

Notes:

1. The above financial results were reviewed by Audit Committee on 12.05.11 and approved by the Board in its meeting held on even date i.e. 12.05.11 and further limited reviewed by the Statutory Auditors of the Company.
2. The above financial results are on stand alone basis.
3. The company is exclusively in the pharmaceutical business segment.
4. On 26.04.2011, the company had repaid FCCB amounting to US\$ 49.7343 millions inclusive of premium of US\$ 16.7343 millions due thereon. Interest for the quarter includes Rs. 1894 lacs, as premium accrued on FCCB for the year 2010-11, which has been ascertained on repayment of FCCB on 26.04.2011. The tax impact of said premium has been considered in current quarter while computing income tax liability for the financial year 2010-11. Since, the FCCBs have been fully redeemed, therefore, the diluted EPS has not been calculated for the current period.
5. The EPS of last year was high due to the weighted average of shares taken for the allotment of - equity shares on Preferential basis and equity shares underlying GDRs, Issue on 20.02.2010 and 26.02.2010, respectively.
6. The company has received approvals from Japanese MOH & South African MCC for 2 of its molecules in API's & has filed 4 DMFs, 3 for US FDA & 1 for Europe, in the quarter ended on March 31, 2011. Thereby, taking the total number of regulatory filings of the company to 18.
7. Status of Complaints:
 - a) Pending at the beginning of Quarter - Nil
 - b) Received During the Quarter - 6
 - c) Disposed Off During the Quarter - 6
 - d) Pending at the end of Quarter - Nil

By Order of the Board of Directors
of Nectar Lifesciences Limited
Sd/-
(Dinesh Dua)

Dated: 12.05.2011

Place: Chandigarh

Chief Executive Officer & Director